Charles Schwab Investment Management Inc. Boosts Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Charles Schwab Investment Management Inc. grew its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 5.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,887,994 shares of the biotechnology company's stock after purchasing an additional 102,860 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.91% of BioCryst Pharmaceuticals worth $14,349,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of BCRX. Intech Investment Management LLC purchased a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at approximately $412,000. Counterweight Ventures LLC increased its position in shares of BioCryst Pharmaceuticals by 591.7% in the 3rd quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company's stock valued at $710,000 after purchasing an additional 79,884 shares during the last quarter. Aigen Investment Management LP boosted its holdings in shares of BioCryst Pharmaceuticals by 75.0% in the 3rd quarter. Aigen Investment Management LP now owns 28,661 shares of the biotechnology company's stock valued at $218,000 after buying an additional 12,280 shares in the last quarter. Principal Financial Group Inc. raised its position in BioCryst Pharmaceuticals by 1,058.1% in the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock valued at $3,127,000 after purchasing an additional 375,890 shares during the last quarter. Finally, Rice Hall James & Associates LLC raised its position in BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company's stock worth $16,444,000 after buying an additional 84,102 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on BCRX. Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 5th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Needham & Company LLC reissued a "buy" rating and set a $14.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.60.

BioCryst Pharmaceuticals Stock Up 1.6 %

BioCryst Pharmaceuticals stock traded up $0.12 during midday trading on Monday, hitting $7.73. 649,237 shares of the stock were exchanged, compared to its average volume of 2,872,478. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.88. The company has a fifty day simple moving average of $7.58 and a two-hundred day simple moving average of $7.35.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. The business's revenue for the quarter was up 35.1% on a year-over-year basis. During the same period last year, the company posted ($0.19) earnings per share. As a group, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.